All articles tagged with #stem cell transplant
A German man, Berlin 2, remains in HIV remission six years after a stem cell transplant from a donor with only one copy of the CCR5 Δ32 mutation, suggesting new avenues for HIV treatment beyond rare donor matches, and highlighting the potential of reservoir reduction and immune system rebuilding in achieving long-term remission.
A study from Ireland highlights the complex physical and emotional challenges faced by multiple sclerosis (MS) patients undergoing autologous hematopoietic stem cell transplant (HSCT). The research emphasizes the need for a comprehensive, multidisciplinary care approach to support patients throughout the treatment process. Interviews with 12 MS patients revealed themes of balancing hope and fear, emotional and physical recovery challenges, and adjusting to treatment outcomes. Despite varied experiences, most patients expressed no regrets about undergoing HSCT, though further research is needed to better understand patient perspectives and decision-making.
Beth Kitchin, a healthy dietitian and runner, initially mistook leg pain for a running injury, but an MRI revealed tumors, leading to a diagnosis of acute lymphoblastic leukemia. After undergoing intensive chemotherapy and a stem cell transplant, she faced complications but is now recovering and advocating for affordable medicine.
Johanna Mendoza, 22, was diagnosed with acute lymphocytic leukemia after developing red splotches on her skin while on vacation in Mexico. She needed a blood stem cell transplant and underwent chemotherapy. Despite her twin sister and half brother not being matches, a clinical trial quickly found a partial bone marrow match for her. The trial investigated post-transplant medication to prevent graft-versus-host disease, and Mendoza's successful transplant has made her cancer-free. Catherine Vega, a stranger who donated her stem cells, shares her experience to encourage others facing challenges.
A man in California, Paul Edmonds, has achieved remission from both acute myelogenous leukemia and HIV after receiving a stem cell transplant with HIV-resistant donor cells. This remarkable treatment, detailed in the New England Journal of Medicine, makes Edmonds only the fifth-known person in the world to achieve remission from both illnesses. His case demonstrates the potential for personalized treatments for older adults with blood cancers and HIV, offering hope for others living with these conditions.
68-year-old Paul Edmonds has been effectively cured of both HIV and leukemia following a breakthrough stem cell transplant in 2019, making him one of only five people in the world to achieve full remission of HIV. The transplant donor had a rare genetic mutation that makes people immune to most types of HIV, and Edmonds received the treatment at City of Hope in California. This success story offers hope for people living with HIV and leukemia, demonstrating the potential of stem cell transplants in treating these diseases.
Paul Edmonds, a 68-year-old patient, has been virtually healed of acute myelogenous leukaemia and is in remission for HIV after a transformative stem cell transplant at a California-based cancer treatment hospital. He is one of just five persons in the world to achieve complete remission from the virus, having carried HIV for over 31 years. This medical breakthrough follows the case of Timothy Ray Brown, the "Berlin patient," who became the first person to achieve HIV remission and cure himself of the virus and leukaemia through similar treatment.
Paul Edmonds, a 68-year-old man from California, is "extremely grateful" to be essentially cured of acute myelogenous leukemia and in HIV remission five years after receiving a stem cell transplant. He is one of only five people in the world to achieve full remission of HIV, having had the virus for over 31 years. The stem cells used in his transplant had a rare HIV-resistant gene mutation. Edmonds will be considered cured of HIV after ceasing antiretroviral therapy for five years. This success follows similar cases, including the "Berlin patient" and a New York woman, indicating progress in the treatment of HIV and leukemia through stem cell transplants.
A 68-year-old man, Paul Edmonds, expresses extreme gratitude after being essentially cured of acute myelogenous leukemia and achieving HIV remission following a stem cell transplant at City of Hope. He is one of only five people in the world to achieve full remission of HIV, having had the virus for over 31 years. This remarkable treatment marks a significant medical breakthrough, with Edmonds being the fifth and oldest person to be in remission for HIV.
A 68-year-old California man, Paul Edmonds, has been cured of both HIV and blood cancer after receiving a rare stem cell treatment. Diagnosed with AIDS in 1988, he underwent a stem cell transplant in 2019, which not only cured his leukemia but also rid his body of HIV. This makes him one of only five people worldwide to achieve HIV remission from a stem cell transplant. The medical team at City of Hope clinic in California is hopeful that personalized treatments for blood cancers, particularly in older patients with HIV, will become more common in the future.
Californian man Paul Edmonds, who had both cancer and HIV, has been free of both diseases since a stem cell transplant five years ago. The treatment has put him in remission from acute myelogenous leukemia and could potentially cure his HIV in another two years. The donated stem cells came with a genetic mutation that makes people resistant to HIV, and after the transplant, Edmonds showed no signs of either AML or HIV. This case has shown that older patients undergoing reduced-intensity conditioning HCT for cancer treatment may be cured of HIV-1 infection, but stem cell transplants come with substantial risks and are only viable for those with life-threatening blood cancers.
Pascal Olhats, a well-known Orange County chef, expressed gratitude towards his daughter in France and his medical team at UCI Health for giving him a chance to beat his rare and aggressive blood cancer. Stem cells donated by his daughter were successfully transplanted at the UCI Health Chao Family Comprehensive Cancer Center, the only place in Orange County offering the bone marrow transplant program he needed. Despite the complexity and risks involved in the procedure, Olhats remained positive and credited his passion for food and the support of his family for his strength. The medical team emphasized the importance of a positive attitude in the recovery process. Olhats is now looking forward to continuing his culinary courses at Saddleback College.
A study comparing stem cell transplant with the drug Lemtrada in treating multiple sclerosis (MS) found that stem cell transplant outperformed Lemtrada in terms of MRI activity, relapses, and disability worsening. However, researchers noted that Lemtrada may be effective in halting disability progression in the early stages of highly active relapsing-remitting MS. In another study, an artificial intelligence (AI) tool called iQ-MS showed promise in accurately quantifying MS lesion volume and brain atrophy, outperforming human radiologists in identifying new or enlarging lesions. While AI tools have limitations, they have the potential to enhance MS research and precision management of individual patients.
Two girls with beta thalassemia, a deadly blood disease, have become the first patients on the West Coast to receive a pioneering gene therapy offered by UCSF Benioff Children's Hospital Oakland. The therapy, called Zynteglo, uses an engineered virus to deliver a healthy gene into patient cells, aiming to permanently cure the disease. The treatment has shown promising results, with one of the girls already feeling better after 10 weeks. The therapy offers hope for an estimated 1,300 to 1,500 patients with beta thalassemia and opens up possibilities for treating other inherited disorders caused by single gene mutations. However, the treatment is expensive, costing $2.8 million for a single-use vial.
A recent study in Sweden found that autologous hematopoietic stem cell transplant (aHSCT) was safe and effective in treating relapsing-remitting multiple sclerosis (RRMS), with nearly three-quarters of patients showing no signs of disease activity after five years. Another study showed that Lemtrada, a disease-modifying therapy, maintained its therapeutic effects on relapse rates, disability, and MRI outcomes over 11 years. Additionally, a survey of neurologists revealed that high-efficacy therapies are often recommended as initial treatment for older adults with MS, and there should be no arbitrary age barrier to aggressive treatment.